29-May-2026
PRNewswire (Wed, 27-May 9:52 AM ET)
Globe Newswire (Thu, 21-May 8:00 AM ET)
Globe Newswire (Thu, 14-May 8:00 AM ET)
Globe Newswire (Mon, 11-May 8:00 AM ET)
Apyx Medical Corporation Reports First Quarter 2026 Financial Results
Globe Newswire (Thu, 7-May 7:00 AM ET)
Globe Newswire (Thu, 23-Apr 8:00 AM ET)
Renuvion wins 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener"
PRNewswire (Wed, 1-Apr 9:30 AM ET)
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Tue, 10-Mar 7:00 AM ET)
Market Chameleon (Thu, 4-Dec 6:55 AM ET)
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
Apyx Medical trades on the NASDAQ stock market under the symbol APYX.
As of May 29, 2026, APYX stock price declined to $3.99 with 109,236 million shares trading.
APYX has a beta of 1.12, meaning it tends to be more sensitive to market movements. APYX has a correlation of 0.03 to the broad based SPY ETF.
APYX has a market cap of $167.29 million. This is considered a Micro Cap stock.
Last quarter Apyx Medical reported $12 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.06.
In the last 3 years, APYX traded as high as $7.97 and as low as $.76.
The top ETF exchange traded funds that APYX belongs to (by Net Assets): VTI, VXF, IWC, DFAC.
APYX has outperformed the market in the last year with a return of +149.7%, while the SPY ETF gained +29.5%. In the last 3 month period, APYX beat the market returning +22.2%, while SPY returned +10.5%. However, in the most recent 2 weeks APYX has underperformed the stock market by returning -1.4%, while SPY returned +2.3%.
APYX support price is $3.87 and resistance is $4.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APYX shares will trade within this expected range on the day.